Cerulean to Present on Nanopharmaceutical Platform at Two Major European Conferences

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company’s senior executives will be presenting at two major European conferences to be held in Munich and Berlin, Germany.

Oliver Fetzer, Ph.D., president and chief executive officer of Cerulean, is scheduled to present at the 16th Annual BIO-Europe 2010 partnering conference, to be held in Munich, Germany. The presentation is scheduled for Tuesday, November 16, 2010, at 10:00 a.m., at the International Congress Center Munich. In his presentation, Dr. Fetzer will brief attendees on the most recent progress in Cerulean’s key programs, including its lead clinical candidate, CRLX101, and its pre-clinical docetaxel nanopharmaceutical program. Additionally, Dr. Fetzer will highlight the versatility of the company’s nanopharmaceutical platform and its potential partnering opportunities.

Cerulean Chief Medical Officer John Ryan, Ph.D., M.D., and Senior Director of Research Scott Eliasof, Ph.D., are scheduled to present at the 22nd EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics,” to be held in Berlin, Germany. The Cerulean presentations are scheduled for Thursday, November 18, 2010, at the Estrel Berlin Hotel and Convention Center. At the symposium, Dr. Ryan will detail critical findings from the completed Phase 1 clinical study of CRLX101. Specifically, Dr. Ryan will highlight observations of progression free disease of greater than six months in five advanced cancer patients who had previously relapsed and progressed on multiple lines of prior therapy. Concurrently, Dr. Eliasof’s presentation will feature results on the Company’s pre-clinical lead candidate, CRLX288, a docetaxel nanopharmaceutical, demonstrating its highly favorable tolerability, extended pharmacokinetics, and superior efficacy in a broad range of xenograft models.

Source: http://www.ceruleanrx.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cerulean Pharma. (2019, February 13). Cerulean to Present on Nanopharmaceutical Platform at Two Major European Conferences. AZoNano. Retrieved on October 11, 2024 from https://www.azonano.com/news.aspx?newsID=20526.

  • MLA

    Cerulean Pharma. "Cerulean to Present on Nanopharmaceutical Platform at Two Major European Conferences". AZoNano. 11 October 2024. <https://www.azonano.com/news.aspx?newsID=20526>.

  • Chicago

    Cerulean Pharma. "Cerulean to Present on Nanopharmaceutical Platform at Two Major European Conferences". AZoNano. https://www.azonano.com/news.aspx?newsID=20526. (accessed October 11, 2024).

  • Harvard

    Cerulean Pharma. 2019. Cerulean to Present on Nanopharmaceutical Platform at Two Major European Conferences. AZoNano, viewed 11 October 2024, https://www.azonano.com/news.aspx?newsID=20526.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.